Let’s call it the Battle of New Orleans, 2015.
As I write this, I am traveling from a meeting of the New Orleans City Council where testimony was heard regarding a new ordinance which would prohibit smoking in the city’s famed bars and the local casino.
As noted by Councilwoman LaToya Cantrell-who is the lead sponsor of the bill and who chaired the meeting–at the end of the hearing, it is a topic which has certainly engendered a lot of discussion among the residents of this iconic American city. Even when sitting in the airport the morning after the meeting I happened to overhear a gentleman near me intensely discussing the merits of the recommendations on the phone with a friend.
But loudest among the many voices were the sweet sounds that came from the musicians who provided testimony to the Council. There was no opposition from the music world: these artists earn their living inhaling the smoke of others, and they came out loud and clear about the need and benefit of being able to provide us entertainment in a healthier, smoke-free environment. As one of them noted a performer doesn’t have to consume a bit of every alcoholic … Continue reading →
What if you were sitting in the room with some of the best financial and scientific minds in the country and someone asked how many of you would be willing to contribute a modest sum of money to create a company with the potential of speeding up the evaluation of drugs that could revolutionize cancer treatment?
That was the opening question of a fascinating meeting I attended recently at the Massachusetts Institute of Technology, one where I didn’t want to leave my seat for a moment for fear I would miss another thought-provoking comment or idea.
The meeting was called CanceRX 2014, and for two solid days about 300 participants listened, debated, and engaged in discussion on how to make that scenario happen. No small task, to be certain. But in this era of ever increasing research discoveries of new treatment targets, it is clear that we need some innovative thinking to take what we learn in the laboratory to the bedsides of the patients we care for. And to make that happen we need as much “out of the box” thinking as we can muster. [more]
Let’s assume that we can continue to accomplish the grand goals … Continue reading →
I had an interesting day this past week. Sadly, it left me wondering why the same “hope and hype” directed at cancer patients and their families decades ago when I started my oncology career was still alive and well today. But then, maybe I am the naïve one to think that anything should have really changed.
In the morning I found out that a story I had been interviewed for a story which appeared on the Kaiser Health News website. A discussion about proton beam therapy for cancer (PBT), it basically pointed out that insurers aren’t necessarily paying for the treatment and that the information supporting its use is not as definitive as some would hope or claim.
Not long after, I was informed of an online discussion on Twitter (called a “tweet chat” at #protonbeam) being hosted by a major medical institution and a well-known weekly newsmagazine on the very topic of proton beam therapy, or PBT. What I watched unfold over the hour-long discussion was what I call a “scrum” of doctors and public relations people promoting proton beam therapy as the answer to many cancer treatment dilemmas with nary a word about the limitations of our … Continue reading →
I had the privilege this week to serve as the keynote speaker for the 4th Summit sponsored by Latinas Contra Cancer-an organization founded and led by Ysabel Duron, a formidable cancer survivor and news media presence in San Francisco.
Bringing together members of the Latino community, researchers, community health workers, promotores (more on that later) and advocates, the summit focused on the issues facing the Latino community in increasing awareness, access to care, improved treatment and research opportunities among other topics. But what was most impressive was the spirit, engagement and commitment that permeated the room for the two days of the meeting.
I would like to share with you some of what I learned during the preparation for that lecture, as well as some observations that tie together the impact and calls to action that are relevant to the Latino community and many other ethnic and socioeconomic groups in the United States. (You may wish to refer to the American Cancer Society’s “Cancer Facts and Figures for Hispanics/Latinos 2012-2014” which contains a wealth of information relative to cancer for this community.) [more]
When one takes a closer look at the Latino community, one finds there are … Continue reading →
As in years past, the trip home from the Annual Meeting of the American Society of Clinical Oncology in Chicago gives me a moment to reflect on what I have heard and hopefully learned over the past five days.
This meeting is a whirlwind of activity and information, far too much for any one person to absorb and process. You can be focused on one topic, you can be general, and you can hear new cutting edge research or be educated on topics of general interest in cancer. You can go to the exhibit hall and be overwhelmed by the booths and displays (I tend not to go there, but obviously many others do). I suspect you get the idea.
Ultimately for me it is the take away messages about trends in cancer research and cancer care that matter the most personally. And this year the trends appear to be somewhat similar to past years, with perhaps some new wrinkles. What is undeniable is that if immunotherapy is the queen at the ball, then “panomics” (I really like that word) holds the keys to the kingdom. [more]
As I started with last week, the cost of drugs is on the … Continue reading →
I had the opportunity earlier this week to participate in a Twitter chat on the topic of colorectal cancer awareness. The chat was intended to bring attention to a nationwide campaign called “80 by 2018” designed to increase colorectal cancer screening rates to 80% of the population over the next 4 years. If it is successful, we should see a decline in both incidence and deaths from this disease.
But I am haunted by two of the comments I tweeted during the session chat that won’t leave my conscience:
“As a doc, you don’t forget the patients you couldn’t help. And you celebrate those you did. #CRCawareness is key #80by2018“
“Let’s remember that screening doesn’t help everyone, so don’t forget the need for more research in understanding #CRC #80by2018“
While we celebrate the opportunity to save more lives with screening, we cannot ignore or forget those for whom screening for colorectal cancer (or other cancers, for that matter) couldn’t or didn’t make a difference. [more]
Let me share a couple of stories with you. These are obviously people I have remembered over the years and who have had a continued impact for me personally.
The first person … Continue reading →
A newspaper story last week caught my eye when it headlined: “Senators Revive Push for End-of-Life-Care Planning.” It reported on new legislation making the rounds in Washington to address care planning for those with advanced illnesses.
You remember “end of life care planning,” don’t you? It was part of the Affordable Care Act debate several years ago, and quickly became translated into “death panels” where opponents made the argument that the government wanted to help people decide not to receive needed treatment. That was a moment that will live in my memory forever, and it’s not a pleasant memory.
So here we are with this new bill, and a headline that suggests we may be headed down the same path once again. This time, however, I hope we can have a more rational and appropriate discussion about an issue that is rapidly evolving in cancer care, supported by medical evidence and medical professionals, not to mention organizations like the American Cancer Society who believe the time has come to engage our patients, their families and caregivers, and the nation at large in understanding the need for compassion as we care for patients with serious illness, including cancer. [more]
First of … Continue reading →
As we walk the halls and sit in the lectures at the annual meeting of the American Society of Clinical Oncology, there’s an elephant in the room. It is right there in front of us, but not many of us seem willing to talk about it. Fewer still are making any commitments to do something about it.
So what is this ubiquitous juxtaposition that is right in front of us but we can’t seem to see?
It is the contrast between incredibly sophisticated science and computer data that will help us understand cancer and its treatment vs. the reality that we can’t have medical records that really work. It is the fact that we have million dollar machines to treat cancer but we have tens of thousands of lives lost to cervical cancer in underdeveloped and underserved countries that could be saved with saved using vinegar. It is cancer care’s version of the “guns vs. butter” debate of the 1960s. [more]
Yesterday there was a large plenary session where thousands of people from around the world sat and listened to the “top” abstracts presented to the assembled masses. These 5 papers represented what the meeting’s scientific advisors thought were … Continue reading →
One hundred years.
That is a long time. And although thriving, remaining relevant and engaged for 100 years is a remarkable accomplishment for any organization, the American Cancer Society today takes pride not only in reflecting on the accomplishments of the last 100 years but also in our commitment to continue the fight, and make this century cancer’s last.
A lot will be written about the remarkable accomplishments of the Society over the past century. The American Cancer Society takes pride in the fact that it has been able to serve millions of people during that time. It has put its mark on numerous improvements in the science and treatment of cancer. We have made incredible strides in understanding cancer, what causes it and what influences it, including the role of tobacco and overweight/obesity. We have funded 46 Nobel Prize winners at some time during their careers, frequently when they needed a start to develop their theory which led to great discoveries. And we have funded numerous investigators who have made other important and lifesaving contributions to understanding cancer and reducing its burden.
But the list is not complete. There is still too much we don’t understand about cancer, its … Continue reading →
April is National Minority Health Month.
That’s the “dry” statement. The impact statement is that-unfortunately-for many in this country, this is more than a phrase. It’s a reality that their health and their health care are in crisis. And the sooner more of us understand this, the sooner we can make a genuine effort to implement effective strategies that will address the sad state of affairs many people find themselves in when it comes to their health, and preventing and appropriately treating their diseases.
This is about more than high blood pressure and diabetes. It’s about heart disease and stroke and cancer and the list goes on. This is about neighborhoods were residents don’t have a place to walk or may even have fear of walking outside their homes. This is about people living in communities where they can’t find affordable, fresh vegetables and healthier foods. This is about not having access to a regular source of medical care, or getting timely treatment for conditions such as breast cancer which many of us take for granted. It is about assuring equitable and quality treatment once diagnosed. This is about the lack of trained health professionals from these communities who … Continue reading →